NDAORALCAPSULE, EXTENDED RELEASE3 Generics Approved
Approved
Dec 1991
Lifecycle
LOE Approaching
Competitive Pressure
60/100
Data completeness
3/8 — Basic
Drug data last refreshed 12h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CARDIZEM CD is an extended-release oral capsule formulation of diltiazem hydrochloride, a calcium channel blocker approved in 1991. It is indicated for hypertension and angina pectoris by reducing cardiac workload and dilating coronary arteries. The drug works by blocking calcium influx into vascular smooth muscle and cardiac tissue, leading to vasodilation and reduced heart rate.
$3MPart D
LOE ApproachingWith LOE approaching and only $3M in Part D spending, this product is in defensive mode; expect smaller brand teams focused on retention and generic transition management.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on CARDIZEM CD offers limited career growth given its LOE-approaching status and minimal linked job openings. Professionals on this team will focus on protecting market share, managing generic transition, and cost containment rather than innovation or expansion.
Brand ManagerField Sales Representative
Worked on CARDIZEM CD at Bausch + Lomb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.